Investor Deck update, SPP Closes 18 December 2024, 5pm
Filed with ASX · · 22 pages · English
The investor presentation has been updated following the commencement of launch activities for Nitroglycerin 0.4%, Ointment. The FDA recently notified Acrux that the submission has been approved, product has been manufactured and Acrux’s licensee, TruPharma has commenced its commercial launch activities for the of the product in the US market. The Company is currently offering a Share Purchase Pla
In the deck
Earlier from Acrux
- Commercialisation of Nitroglycerin Ointment
- Share Purchase Plan Offer Booklet
- Investor Presentation
- Share Placement successfully concluded and SPP launched
- FDA Approval - Nitroglycerin Ointment
Later from Acrux
- Acrux raises $1.34 million from SPP
- Launch of 90 gram pack size of Dapsone 5%, Gel in US
- Monthly Activities/Appendix 4C Cash Flow Report
- Acrux CEO announces plan to retire
- Appendix 4D and December 2024 Half Year Accounts
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux